vimarsana.com

Latest Breaking News On - Simple endoscopic score - Page 8 : vimarsana.com

FDA OKs Risankizumab for Crohn's Disease

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou.

United-states
Japan
Calgary
Alberta
Canada
California
San-diego
Spring-house
British-columbia
Horsham
Saskatchewan
Americans

TNF Blockers Beat Newer Biologics in Crohn's Disease

TNF Blockers Beat Newer Biologics in Crohn's Disease
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
Canada
Toronto
Ontario
American
Neeraj-narula
Simon-hong
Pfizer
Mcmaster-university
Novartis
Western-europe

Endoscopic Healing of Crohn's Disease Could Differ by Biologic

Infliximab biosimilar and adalimumab resulted in better endoscopic healing rates than either vedolizumab or ustekinumab in a post hoc pooled analysis.

Neeraj-narula
Amgen
Pfizer
Mcmaster-university
Colitis-organisation
Pivotal-trial-program-data
Hamilton-health-sciences
Janssen-research-developmen
European-crohn
Hamilton-health
Simple-endoscopic-score
Janssen-research

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Disease-activity-index
Simple-endoscopic-score
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.